Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5721
Peer-review started: April 5, 2023
First decision: May 15, 2023
Revised: May 24, 2023
Accepted: August 3, 2023
Article in press: August 3, 2023
Published online: August 26, 2023
Processing time: 141 Days and 19.4 Hours
Malignant melanoma of the prostate is rare. Twenty-five studies describing 45 cases have been reported. Prostate melanoma is characterized by an insidious onset and poor prognosis. The prognosis and treatment vary according to primary or secondary melanoma.
A 75-year-old man attended the hospital due to low back pain of 2 mo duration. He denied a history of trauma or abnormal urinary symptoms. Digital rectal examination showed indentation in the left lobe of the prostate, 1 cm in diameter. His prostate-specific antigen was 5.6 ng/mL and 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) showed focal glucose metabolism in the left lobe. Imaging showed bone metastases to T12 and bilateral ribs. Transperineal prostate biopsy was done and three tissue specimens on the left side showed prostate adenocarcinoma (Gleason score 3 + 3 = 6), but the specimen on the right side showed malignant melanoma. The patient underwent T12 tumor resection and pathology findings indicated metastatic malignant melanoma. The patient underwent gastroscopy and colonoscopy, and gastroscopy revealed multiple mucosal black spots in the gastric body and fundus. The patient was diagnosed with secondary malignant prostate melanoma and primary gastric disease.
Diagnosis of primary prostate melanoma requires caution and 18F-FDG-PET/CT may result in false-negative detection of melanoma.
Core Tip: Malignant melanoma of the prostate is rare. To date, 25 studies describing 45 cases have been reported. There is a significant difference in prognosis between primary and secondary cases. We report a case of secondary malignant prostate melanoma with primary gastric disease. We also review the literature on 10 cases of primary prostate melanoma, and found that most cases did not receive sufficient tests and 18F-fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG-PET/CT) was false-negative. We conclude that caution should be used in the diagnosis of primary prostate melanoma, and 18F-FDG-PET/CT may result in false-negative detection of melanoma.